帕金森病中的人工智能:早期检测和诊断进展。

IF 12.5 1区 医学 Q1 CELL BIOLOGY Ageing Research Reviews Pub Date : 2024-07-05 DOI:10.1016/j.arr.2024.102410
Aananya Reddy , Ruhananhad P. Reddy , Aryan Kia Roghani , Ricardo Isaiah Garcia , Sachi Khemka , Vasanthkumar Pattoor , Michael Jacob , P. Hemachandra Reddy , Ujala Sehar
{"title":"帕金森病中的人工智能:早期检测和诊断进展。","authors":"Aananya Reddy ,&nbsp;Ruhananhad P. Reddy ,&nbsp;Aryan Kia Roghani ,&nbsp;Ricardo Isaiah Garcia ,&nbsp;Sachi Khemka ,&nbsp;Vasanthkumar Pattoor ,&nbsp;Michael Jacob ,&nbsp;P. Hemachandra Reddy ,&nbsp;Ujala Sehar","doi":"10.1016/j.arr.2024.102410","DOIUrl":null,"url":null,"abstract":"<div><p>Parkinson’s disease (PD) is the second most common neurodegenerative disorder, globally affecting men and women at an exponentially growing rate, with currently no cure. Disease progression starts when dopaminergic neurons begin to die. In PD, the loss of neurotransmitter, dopamine is responsible for the overall communication of neural cells throughout the body. Clinical symptoms of PD are slowness of movement, involuntary muscular contractions, speech &amp; writing changes, lessened automatic movement, and chronic tremors in the body. PD occurs in both familial and sporadic forms and modifiable and non-modifiable risk factors and socioeconomic conditions cause PD. Early detectable diagnostics and treatments have been developed in the last several decades. However, we still do not have precise early detectable biomarkers and therapeutic agents/drugs that prevent and/or delay the disease process. Recently, artificial intelligence (AI) science and machine learning tools have been promising in identifying early detectable markers with a greater rate of accuracy compared to past forms of treatment and diagnostic processes. Artificial intelligence refers to the intelligence exhibited by machines or software, distinct from the intelligence observed in humans that is based on neural networks in a form and can be used to diagnose the longevity and disease severity of disease. The term Machine Learning or Neural Networks is a blanket term used to identify an emerging technology that is created to work in the way of a “human brain” using many intertwined neurons to achieve the same level of raw intelligence as that of a brain. These processes have been used for neurodegenerative diseases such as Parkinson’s disease and Alzheimer’s disease, to assess the severity of the patient’s condition. In the current article, we discuss the prevalence and incidence of PD, and currently available diagnostic biomarkers and therapeutic strategies. We also highlighted currently available artificial intelligence science and machine learning tools and their applications to detect disease and develop therapeutic interventions.</p></div>","PeriodicalId":55545,"journal":{"name":"Ageing Research Reviews","volume":null,"pages":null},"PeriodicalIF":12.5000,"publicationDate":"2024-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Artificial intelligence in Parkinson's disease: Early detection and diagnostic advancements\",\"authors\":\"Aananya Reddy ,&nbsp;Ruhananhad P. Reddy ,&nbsp;Aryan Kia Roghani ,&nbsp;Ricardo Isaiah Garcia ,&nbsp;Sachi Khemka ,&nbsp;Vasanthkumar Pattoor ,&nbsp;Michael Jacob ,&nbsp;P. Hemachandra Reddy ,&nbsp;Ujala Sehar\",\"doi\":\"10.1016/j.arr.2024.102410\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Parkinson’s disease (PD) is the second most common neurodegenerative disorder, globally affecting men and women at an exponentially growing rate, with currently no cure. Disease progression starts when dopaminergic neurons begin to die. In PD, the loss of neurotransmitter, dopamine is responsible for the overall communication of neural cells throughout the body. Clinical symptoms of PD are slowness of movement, involuntary muscular contractions, speech &amp; writing changes, lessened automatic movement, and chronic tremors in the body. PD occurs in both familial and sporadic forms and modifiable and non-modifiable risk factors and socioeconomic conditions cause PD. Early detectable diagnostics and treatments have been developed in the last several decades. However, we still do not have precise early detectable biomarkers and therapeutic agents/drugs that prevent and/or delay the disease process. Recently, artificial intelligence (AI) science and machine learning tools have been promising in identifying early detectable markers with a greater rate of accuracy compared to past forms of treatment and diagnostic processes. Artificial intelligence refers to the intelligence exhibited by machines or software, distinct from the intelligence observed in humans that is based on neural networks in a form and can be used to diagnose the longevity and disease severity of disease. The term Machine Learning or Neural Networks is a blanket term used to identify an emerging technology that is created to work in the way of a “human brain” using many intertwined neurons to achieve the same level of raw intelligence as that of a brain. These processes have been used for neurodegenerative diseases such as Parkinson’s disease and Alzheimer’s disease, to assess the severity of the patient’s condition. In the current article, we discuss the prevalence and incidence of PD, and currently available diagnostic biomarkers and therapeutic strategies. We also highlighted currently available artificial intelligence science and machine learning tools and their applications to detect disease and develop therapeutic interventions.</p></div>\",\"PeriodicalId\":55545,\"journal\":{\"name\":\"Ageing Research Reviews\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":12.5000,\"publicationDate\":\"2024-07-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Ageing Research Reviews\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1568163724002289\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CELL BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ageing Research Reviews","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1568163724002289","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CELL BIOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

帕金森病(Parkinson's disease,PD)是第二大常见的神经退行性疾病,在全球范围内影响着男性和女性,且发病率呈指数级增长,目前尚无法治愈。当多巴胺能神经元开始死亡时,疾病就开始恶化。在帕金森氏症中,神经递质多巴胺的丧失负责全身神经细胞的整体交流。帕金森氏症的临床症状是行动迟缓、肌肉不自主收缩、语言和书写改变、自动运动减少以及身体长期震颤。肢端麻痹症有家族性和散发性两种形式,可改变和不可改变的风险因素以及社会经济条件都会导致肢端麻痹症。在过去的几十年中,已经开发出了可早期检测的诊断和治疗方法。然而,我们仍然没有精确的早期检测生物标志物和治疗剂/药物来预防和/或延缓疾病进程。最近,人工智能(AI)科学和机器学习工具在确定早期检测标记物方面大有可为,与过去的治疗和诊断过程相比,准确率更高。人工智能是指机器或软件表现出的智能,有别于人类观察到的智能,它以神经网络的形式为基础,可用于诊断疾病的长短和严重程度。机器学习 "或 "神经网络 "是一个总称,用来指代一种新兴技术,这种技术以 "人脑 "的方式工作,使用许多交织在一起的神经元,以达到与大脑相同的原始智能水平。这些程序已被用于帕金森病和阿尔茨海默病等神经退行性疾病,以评估患者病情的严重程度。在这篇文章中,我们讨论了帕金森病的患病率和发病率,以及目前可用的诊断生物标记物和治疗策略。我们还重点介绍了目前可用的人工智能科学和机器学习工具及其在检测疾病和开发治疗干预措施方面的应用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Artificial intelligence in Parkinson's disease: Early detection and diagnostic advancements

Parkinson’s disease (PD) is the second most common neurodegenerative disorder, globally affecting men and women at an exponentially growing rate, with currently no cure. Disease progression starts when dopaminergic neurons begin to die. In PD, the loss of neurotransmitter, dopamine is responsible for the overall communication of neural cells throughout the body. Clinical symptoms of PD are slowness of movement, involuntary muscular contractions, speech & writing changes, lessened automatic movement, and chronic tremors in the body. PD occurs in both familial and sporadic forms and modifiable and non-modifiable risk factors and socioeconomic conditions cause PD. Early detectable diagnostics and treatments have been developed in the last several decades. However, we still do not have precise early detectable biomarkers and therapeutic agents/drugs that prevent and/or delay the disease process. Recently, artificial intelligence (AI) science and machine learning tools have been promising in identifying early detectable markers with a greater rate of accuracy compared to past forms of treatment and diagnostic processes. Artificial intelligence refers to the intelligence exhibited by machines or software, distinct from the intelligence observed in humans that is based on neural networks in a form and can be used to diagnose the longevity and disease severity of disease. The term Machine Learning or Neural Networks is a blanket term used to identify an emerging technology that is created to work in the way of a “human brain” using many intertwined neurons to achieve the same level of raw intelligence as that of a brain. These processes have been used for neurodegenerative diseases such as Parkinson’s disease and Alzheimer’s disease, to assess the severity of the patient’s condition. In the current article, we discuss the prevalence and incidence of PD, and currently available diagnostic biomarkers and therapeutic strategies. We also highlighted currently available artificial intelligence science and machine learning tools and their applications to detect disease and develop therapeutic interventions.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Ageing Research Reviews
Ageing Research Reviews 医学-老年医学
CiteScore
19.80
自引率
2.30%
发文量
216
审稿时长
55 days
期刊介绍: With the rise in average human life expectancy, the impact of ageing and age-related diseases on our society has become increasingly significant. Ageing research is now a focal point for numerous laboratories, encompassing leaders in genetics, molecular and cellular biology, biochemistry, and behavior. Ageing Research Reviews (ARR) serves as a cornerstone in this field, addressing emerging trends. ARR aims to fill a substantial gap by providing critical reviews and viewpoints on evolving discoveries concerning the mechanisms of ageing and age-related diseases. The rapid progress in understanding the mechanisms controlling cellular proliferation, differentiation, and survival is unveiling new insights into the regulation of ageing. From telomerase to stem cells, and from energy to oxyradical metabolism, we are witnessing an exciting era in the multidisciplinary field of ageing research. The journal explores the cellular and molecular foundations of interventions that extend lifespan, such as caloric restriction. It identifies the underpinnings of manipulations that extend lifespan, shedding light on novel approaches for preventing age-related diseases. ARR publishes articles on focused topics selected from the expansive field of ageing research, with a particular emphasis on the cellular and molecular mechanisms of the aging process. This includes age-related diseases like cancer, cardiovascular disease, diabetes, and neurodegenerative disorders. The journal also covers applications of basic ageing research to lifespan extension and disease prevention, offering a comprehensive platform for advancing our understanding of this critical field.
期刊最新文献
Understanding exogenous factors and biological mechanisms for cognitive frailty: A multidisciplinary scoping review Targeting senescent cells in atherosclerosis: Pathways to novel therapies Unraveling the protein post-translational modification landscape: Neuroinflammation and neuronal death after stroke Motoric cognitive risk syndrome as a predictive factor of cognitive impairment and dementia – A systematic review and meta-analysis The influence of education in predicting conversion from Subjective cognitive decline (SCD) to objective cognitive impairment: A systematic review and meta-analysis
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1